# Phase 1/2 ovarian cancer trials recruiting: 82 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 82 trials in phase 1/2 for ovarian cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1/2 ovarian cancer trials: 82 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1-2/ovarian-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 82
- Recruiting or not yet: 82
- Read on: November 19, 2026

## Trials

The 25 newest of 82, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 12, 2026 | NCT07933419 | Phase Ib/II Clinical Study of QLS5133 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Clear Cell Renal Cell Carcinoma, Ovarian Cancer, Other Advanced Solid Tumors | 558 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07933419) |
| November 2, 2026 | NCT07909031 | CR-002 in Adult Participants With Locally Advanced or Metastatic Solid Tumors | Crescent Biopharma, Inc. | Phase 1/2 | Recruiting | Head and Neck Squamous Cell Carcinoma (HNSCC) - Recurrent/Metastatic (R/M), Gastric/GEJ, Biliary Tract Cancer (BTC)... | 219 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909031) |
| September 10, 2026 | NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | Advenchen Pharmaceuticals, LLC. | Phase 1/2 | Not yet recruiting | Endometrial Neoplasms, Ovarian Neoplasms, Soft Tissue Sarcoma (STS), Glioblastoma | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07811297) |
| August 21, 2026 | NCT07778498 | A Phase I/II, First-in-Human Study to Evaluate TJ102 in Participants With Advanced or Metastatic Ovarian Cancer and Other Solid Tumors. | Phrontline Biopharma | Phase 1/2 | Recruiting | Ovarian Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07778498) |
| August 7, 2026 | NCT07752875 | A Study of LG00313112 in Participants With Advanced Solid Malignancies Harboring a TP53 Y220C Mutation | LG Chem | Phase 1/2 | Not yet recruiting | Ovarian Cancer, Small Cell Lung Cancer, Non Small Cell Lung Cancer, Colorectal Cancer, Esophageal Cancer, Breast... | 250 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07752875) |
| August 6, 2026 | NCT07749586 | A Study to Evaluate ARV-6723 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors | Arvinas Inc. | Phase 1/2 | Recruiting | Advanced Solid Tumor | 499 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07749586) |
| July 30, 2026 | NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Gilead Sciences | Phase 1/2 | Recruiting | Ovarian Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736937) |
| June 26, 2026 | NCT07670312 | Evaluation of XYA02 in Patients With Advanced Solid Tumors | XYone Therapeutics, Inc | Phase 1/2 | Recruiting | MUC1-expressing Advanced, Relapsed and/or Refractory Solid Tumors, Non-Small Cell Lung Cancer, Ovarian Cancer, GEJ... | 190 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07670312) |
| June 10, 2026 | NCT07637851 | Safety and Efficacy of Ubamatamab With First-line Chemotherapy in Ovarian Cancer | ARCAGY/ GINECO GROUP | Phase 1/2 | Not yet recruiting | Ovarian Cancer | 43 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07637851) |
| June 1, 2026 | NCT07617753 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) pt2 | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07617753) |
| May 29, 2026 | NCT07612891 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Breast Cancer (Locally Advanced or Metastatic), Advanced Solid Cancers, Metastatic (Stage IV) Breast Cancer, Ovarian... | 201 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612891) |
| May 28, 2026 | NCT07610798 | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patients With Advanced... | Shenzhen Ionova Life Sciences Co., Ltd. | Phase 1/2 | Recruiting | Advance Solid Tumors, Colon and Rectal Cancer, Non - Small Cell Lung Cancer NSCLC, Pancreatic Adenocarcinoma Advanced... | 178 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07610798) |
| May 15, 2026 | NCT07589543 | Dual-Target CAR-NK Cells in Recurrent or Refractory Epithelial Ovarian Cancer | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Epithelial Ovarian Cancer, Fallopian Tube or Peritoneum | 42 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07589543) |
| April 13, 2026 | NCT07523529 | Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors | Beijing Biotech | Phase 1/2 | Recruiting | Advanced Unresectable, Metastatic | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07523529) |
| March 18, 2026 | NCT07480954 | Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16) | Beijing Biotech | Phase 1/2 | Recruiting | Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Carcinoma, Recurrent or Refractory Disease... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07480954) |
| March 10, 2026 | NCT07460180 | The PROOV Study: Exploiting the Synergistic Effect of PARP Inhibition With Cisplatin and Hyperthermia During Interval Cytoreductive Surgery... | The Netherlands Cancer Institute | Phase 1/2 | Recruiting | Ovarian Cancer, Epithelial Cancer, Fallopian Tube Cancer | 55 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460180) |
| March 6, 2026 | NCT07453394 | QLS5132 Combination Therapy in Advanced Solid Tumors | Qilu Pharmaceutical Co., Ltd. | Phase 1/2 | Not yet recruiting | Gastric Cancer (GC), Non-small Cell Lung Cancer (NSCLC), Endometrial Cancer, Advanced Solid Tumors, Ovarian Cancer | 626 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453394) |
| February 13, 2026 | NCT07410676 | EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Sarcoma, Leukaemia, Breast Cancer (Locally Advanced or Metastatic), Lung Cancer (Diagnosis), Colorectal Cancer... | 83 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410676) |
| February 13, 2026 | NCT07410494 | Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors | Essen Biotech | Phase 1/2 | Recruiting | Cancer, Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (Locally Advanced or Metastatic), Prostate... | 85 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07410494) |
| February 5, 2026 | NCT07389239 | A Study Evaluating the Immunotherapy Treatment for Ovarian Cancer and Other Advanced Malignancies. | University of Chicago | Phase 1/2 | Recruiting | Ovarian Cancer, Advanced Malignant Solid Tumor | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07389239) |
| January 14, 2026 | NCT07341737 | SL-28 for Advanced Solid Tumours | Second Life Therapeutics | Phase 1/2 | Recruiting | Head & Neck Cancer, Pancreas Carcinoma, Pancreas Cancer, Metastatic, Lung Adenocarcinoma, Lung Cancer (NSCLC), Lung... | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07341737) |
| December 9, 2025 | NCT07273396 | Tolerance, Safety, Efficacy, and Pharmacokinetics of Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) Using Paclitaxel for... | Seoul National University Hospital | Phase 1/2 | Not yet recruiting | Ovarian Neoplasms, Peritoneal Neoplasms | 53 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07273396) |
| September 24, 2025 | NCT07189871 | 177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors | Radiopharm Theranostics, Ltd | Phase 1/2 | Recruiting | Castration-Resistant Prostate Cancer (CRPC), Colorectal Cancer, NSCLC (Non-small Cell Lung Cancer), Ovarian Cancer... | 61 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07189871) |
| September 22, 2025 | NCT07186842 | A Clinical Trial to Test if the Investigational Drug BNT329 is Safe and Potentially Beneficial for People With Advanced Solid Tumors Known... | BioNTech SE | Phase 1/2 | Recruiting | Advanced Solid Cancers | 245 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07186842) |
| August 7, 2025 | NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | Terremoto Biosciences Inc. | Phase 1/2 | Recruiting | Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma, Head and Neck Squamous Cell Carcinoma... | 248 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07109726) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| [Beijing Biotech](https://specstream.ai/data/clinical-trials/company/beijing-biotech) | 4 |
| Essen Biotech | 3 |
| [AstraZeneca](https://specstream.ai/data/clinical-trials/company/astrazeneca) | 3 |
| Jacobio Pharmaceuticals Co., Ltd. | 2 |
| Shenzhen Ionova Life Sciences Co., Ltd. | 2 |
| [Gilead Sciences](https://specstream.ai/data/clinical-trials/company/gilead-sciences) | 2 |
| [Regeneron Pharmaceuticals](https://specstream.ai/data/clinical-trials/company/regeneron-pharmaceuticals) | 2 |
| Hadassah Medical Organization | 2 |
| [Qilu Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/qilu-pharmaceutical-co-ltd) | 2 |
| University of California, Irvine | 2 |
| Icahn School of Medicine at Mount Sinai | 1 |
| The Netherlands Cancer Institute | 1 |
| Filamon LTD | 1 |
| Arvinas Inc. | 1 |
| Heronova Pharmaceuticals | 1 |
| PMV Pharmaceuticals, Inc | 1 |
| Zhejiang Yangli Pharmaceutical Technology Co., Ltd. | 1 |
| Perspective Therapeutics | 1 |
| Tongji Hospital | 1 |
| Advenchen Pharmaceuticals, LLC. | 1 |
| Shanghai Gynecologic Oncology Group | 1 |
| [Evopoint Biosciences Inc.](https://specstream.ai/data/clinical-trials/company/evopoint-biosciences-inc) | 1 |
| Seoul National University Hospital | 1 |
| AtlasMedx, Incorporated | 1 |
| BioMimetix JV, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 46 |
| China | 27 |
| Spain | 18 |
| Australia | 13 |
| United Kingdom | 12 |
| Germany | 10 |
| France | 9 |
| Netherlands | 8 |
| Belgium | 8 |
| Italy | 8 |
| Japan | 8 |
| South Korea | 6 |
| Israel | 5 |
| Canada | 4 |
| Taiwan | 3 |
| Ireland | 3 |
| Ukraine | 2 |
| Brazil | 2 |
| Hungary | 2 |
| Poland | 2 |
| Turkey (Türkiye) | 2 |
| Portugal | 2 |
| Puerto Rico | 2 |
| Sweden | 2 |
| Singapore | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Anesthesiology practices in the United States](https://specstream.ai/data/businesses/anesthesiology-practices/united-states)
- [Wholesale florists in the United States](https://specstream.ai/data/businesses/wholesale-florists/united-states)
- [Ukrainian restaurants in the United States](https://specstream.ai/data/businesses/ukrainian-restaurants/united-states)
- [Tea wholesalers in the United States](https://specstream.ai/data/businesses/tea-wholesalers/united-states)
- [Solar installers in the United States](https://specstream.ai/data/businesses/solar-installers/united-states)
- [Rheumatology practices in the United States](https://specstream.ai/data/businesses/rheumatology-practices/united-states)
